Cargando…

Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

Edoxaban is used for venous thromboembolism (VTE) treatment. Real‐life data are lacking about its use in long‐term therapy. We aimed to assess the efficacy and the safety of edoxaban for long‐term VTE treatment in a real‐life setting. Patients with VTE included in the Registro Informatizado Enfermed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camporese, Giuseppe, Simioni, Paolo, Di Micco, Pierpaolo, Fernández‐Capitán, Carmen, Rivas, Agustina, Font, Carme, Sahuquillo, Joan Carles, Villares, Paula, Prandoni, Paolo, Monreal, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877832/ https://www.ncbi.nlm.nih.gov/pubmed/33038286 http://dx.doi.org/10.1111/cts.12876

Ejemplares similares

Editorial on the Special Issue “The New Frontier of Venous Thromboembolism”
por: Di Micco, Pierpaolo, et al.
Publicado: (2023)

Common Practice in the Treatment of Superficial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV)
por: Camporese, Giuseppe, et al.
Publicado: (2023)

Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria
por: Takama, Takuro, et al.
Publicado: (2019)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Acute venous thromboembolism in patients with brain cancer: clinical course
por: Becattini, Cecilia, et al.
Publicado: (2023)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry
por: Di Micco, Pierpaolo, et al.
Publicado: (2019)

Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project
por: Bernardi, Enrico, et al.
Publicado: (2022)

Risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Hurst, Katherine V, et al.
Publicado: (2016)

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
por: Bortoluzzi, Cristiano, et al.
Publicado: (2022)

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Tellor, Katie B, et al.
Publicado: (2016)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
por: Prandoni, Paolo
Publicado: (2008)

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
por: De Caterina, Raffaele, et al.
Publicado: (2017)

Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry
por: Lorenzo, Alicia, et al.
Publicado: (2022)

Edoxaban treatment for pulmonary arterial thromboembolism associated with azygous vein aneurysm
por: Mochimaru, Takao, et al.
Publicado: (2017)

COVID‐19 and Venous Thromboembolism in Intensive Care or Medical Ward
por: Avruscio, Giampiero, et al.
Publicado: (2020)

Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
por: Weitz, Jeffrey I., et al.
Publicado: (2020)

Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence
por: Zalpour, Ali, et al.
Publicado: (2015)

Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
por: Hara, Nobuhiro, et al.
Publicado: (2017)

Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism
por: Martínez-Urbistondo, Diego, et al.
Publicado: (2021)

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
por: Poletto, Francesco, et al.
Publicado: (2022)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
por: Clay, Emilie, et al.
Publicado: (2018)

Special Issue “COVID-19 and Thrombosis”
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Editorial Comment on the Special Issue Discussing COVID-19 and Thrombosis, Second Edition
por: Di Micco, Pierpaolo, et al.
Publicado: (2023)

The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
por: Ramacciotti, Eduardo, et al.
Publicado: (2018)

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
por: Stacy, Zachary A., et al.
Publicado: (2016)

Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study
por: Grifoni, Elisa, et al.
Publicado: (2022)

Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders
por: Campello, Elena, et al.
Publicado: (2022)

Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study
por: Campello, Elena, et al.
Publicado: (2020)

Venous Thromboembolism in Denmark: Seasonality in Occurrence and Mortality
por: Skajaa, Nils, et al.
Publicado: (2019)

Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism
por: Jara-Palomares, Luis, et al.
Publicado: (2018)

Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
por: Giorgi-Pierfranceschi, Matteo, et al.
Publicado: (2015)

Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry
por: Bertoletti, Laurent, et al.
Publicado: (2013)

Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Blanco-Molina, Angeles, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n3r38k8k6l4qnqu3l1312m7ij8